Elevated serum autoantibody against high mobility group box 1 as a potent surrogate biomarker for amyotrophic lateral sclerosis

Neurobiology of Disease

Volumn 58, Issue , 2013, Pages 13-18

  Hwang, Chi Shin ^a,b   Liu, Guan Ting ^c   Chang, Margaret Dah Tsyr ^a   Liao, I Lin ^d   Chang, Hao Teng ^c,e  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Amyotrophic lateral sclerosis; Autoantibody; Biomarker; Heat shock protein; High mobility group box 1

Indexed keywords

AUTOANTIBODY; HEAT SHOCK PROTEIN 60 ANTIBODY; HEAT SHOCK PROTEIN 70 ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; CELL STRESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOANTIBODY; BIOMARKER; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP BOX 1;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHAPERONIN 60; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HMGB1 PROTEIN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PARKINSON DISEASE; ROC CURVE; TRACHEOTOMY;

EID: 84878483932     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.04.013     Document Type: Article

References (51)

1. Abdulahad D.A., et al. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res. Ther. 2011, 13:R71.
2. Babu G.N., et al. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem. Res. 2008, 33:1145-1149.
3. Baldas V., et al. Anti-transglutaminase antibodies and age. Clin. Chem. 2004, 50:1856-1860.
4. Brooks B.R., et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron. Disord. 2000, 1:293-299.
5. Brown I.R. Heat shock proteins and protection of the nervous system. Ann. N. Y. Acad. Sci. 2007, 1113:147-158.
6. Bruening W., et al. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J. Neurochem. 1999, 72:693-699.
7. Bucciarelli L.G., et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 2002, 59:1117-1128.
8. Casula M., et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011, 179:233-243.
9. Cedarbaum J.M., et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J. Neurol. Sci. 1999, 169:13-21.
10. Chio A., et al. Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. J. Neurol. 1999, 246:175-180.
11. Cronin S., et al. Elevated serum angiogenin levels in ALS. Neurology 2006, 67:1833-1836.
12. Dantes M., McComas A. The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis. Muscle Nerve 1991, 14:416-421.
13. Davenport R.J., et al. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J. Neurol. Neurosurg. Psychiatry 1996, 60:147-151.
14. Dettmers C., et al. Sympathetic skin response abnormalities in amyotrophic lateral sclerosis. Muscle Nerve 1993, 16:930-934.
15. Franklin T.B., et al. The role of heat shock proteins Hsp70 and Hsp27 in cellular protection of the central nervous system. Int. J. Hyperthermia 2005, 21:379-392.
16. Haverkamp L.J., et al. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995, 118(Pt 3):707-719.
17. Hayashi H., Kato S. Total manifestations of amyotrophic lateral sclerosis. ALS in the totally locked-in state. J. Neurol. Sci. 1989, 93:19-35.
18. Henkel J.S., et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004, 55:221-235.
19. Ilzecka J. Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2009, 120:119-122.
20. Ilzecka J., Stelmasiak Z. Anti-annexin V antibodies in the cerebrospinal fluid and serum of patients with amyotrophic lateral sclerosis. Neurol. Sci. 2003, 24:273-274.
21. Kalmar B., et al. Upregulation of heat shock proteins rescues motoneurones from axotomy-induced cell death in neonatal rats. Exp. Neurol. 2002, 176:87-97.
22. Kunst C.B. Complex genetics of amyotrophic lateral sclerosis. Am. J. Hum. Genet. 2004, 75:933-947.
23. Lo Coco D., et al. Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neurosci. Lett. 2007, 412:73-77.
24. Ludolph A.C. Motor neuron disease: urgently needed-biomarkers for amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011, 7:13-14.
25. Lue L.F., et al. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:249-266.
26. Maatkamp A., et al. Decrease of Hsp25 protein expression precedes degeneration of motoneurons in ALS-SOD1 mice. Eur. J. Neurosci. 2004, 20:14-28.
27. Mailhos C., et al. Heat shock protects neuronal cells from programmed cell death by apoptosis. Neuroscience 1993, 55:621-627.
28. Mecocci P., et al. Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. J. Neuroimmunol. 1995, 57:165-170.
29. Mitchell J.D., Borasio G.D. Amyotrophic lateral sclerosis. Lancet 2007, 369:2031-2041.
30. Mitchell R.M., et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009, 72:14-19.
31. Mitsumoto H., et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007, 68:1402-1410.
32. Moreau C., et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?. Neurology 2005, 65:1958-1960.
33. Nagata T., et al. Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Neurol. Res. 2007, 29:772-776.
34. Oey P.L., et al. Subtle involvement of the sympathetic nervous system in amyotrophic lateral sclerosis. Muscle Nerve 2002, 25:402-408.
35. Pratt A.J., et al. Amyotrophic lateral sclerosis: update and new developments. Degener. Neurol. Neuromuscul. Dis. 2012, 2012:1-14.
36. Radunovic A., et al. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol. 2007, 6:913-925.
37. Ranganathan S., et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem. 2005, 95:1461-1471.
38. Ranganathan S., et al. Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects. Amyotroph. Lateral Scler. 2007, 8:373-379.
39. Ryberg H., Bowser R. Protein biomarkers for amyotrophic lateral sclerosis. Expert Rev. Proteomics 2008, 5:249-262.
40. Tanaka M., et al. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2006, 65:816-825.
41. Taylor D.M., et al. Characterizing the role of Hsp90 in production of heat shock proteins in motor neurons reveals a suppressive effect of wild-type Hsf1. Cell Stress Chaperones 2007, 12:151-162.
42. Traynor B.J., et al. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch. Neurol. 2000, 57:109-113.
43. Tsan M.F. Heat shock proteins and high mobility group box 1 protein lack cytokine function. J. Leukoc. Biol. 2011, 89:847-853.
44. Ulloa L., Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006, 17:189-201.
45. Wang M.Y., et al. Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathol. 2009, 118:381-389.
46. Watanabe M., et al. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol. Dis. 2001, 8:933-941.
47. Worms P.M. The epidemiology of motor neuron diseases: a review of recent studies. J. Neurol. Sci. 2001, 191:3-9.
48. Wu T., Tanguay R.M. Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe?. Cell Stress Chaperones 2006, 11:1-12.
49. Wu T.C., et al. Presence of antibodies to heat stress proteins and its possible significance in workers exposed to high temperature and carbon monoxide. Biomed. Environ. Sci. 1996, 9:370-379.
50. Wu T., et al. Association of plasma antibodies against the inducible Hsp70 with hypertension and harsh working conditions. Cell Stress Chaperones 2001, 6:394-401.
51. Zhang H., et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am. J. Respir. Crit. Care Med. 2008, 178:356-362.